Resmetirom for people with MASLD and HIV
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests if resmetirom can help people who have both HIV and a liver condition called MASLD (fat buildup in the liver not caused by alcohol). You may qualify if your liver has a certain amount of fat and stiffness, and your HIV is well controlled with stable medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have HIV.
- You have been diagnosed with MASLD (fatty liver disease) through an imaging test or liver biopsy in the last 12 months.
- A special MRI shows your liver fat is at least 8%.
- A liver stiffness test (VCTE) shows a score of 8 kPa or higher and a CAP score of 263 dB/m or higher.
- Your HIV is well controlled (viral load under 200 copies/mL) for at least 6 months, and you're on a stable HIV medication plan for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at fat buildup in the liver (fatty liver disease) in people with and without HIV. It uses blood tests to understand the liver's fat content and how it relates to HIV, which may help improve future care.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
This trial tests if resmetirom can help people with MASH, a type of fatty liver disease linked to metabolic issues like diabetes or obesity. It looks at how safe and effective the drug is over time.
This study tests a daily pill, resmetirom, to see if it can reduce fat and scarring in the livers of children and teens with MASH, a type of fatty liver disease. It may help improve liver health and prevent further damage.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.